|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1993-2-5
|
|
pubmed:abstractText |
To determine the clinical and laboratory characteristics and outcomes of patients with chronic myelogenous leukemia (CML) in the lymphoid blastic phase.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0002-9343
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
94
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
69-74
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:8420302-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8420302-Blast Crisis,
pubmed-meshheading:8420302-Humans,
pubmed-meshheading:8420302-Incidence,
pubmed-meshheading:8420302-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:8420302-Prognosis,
pubmed-meshheading:8420302-Survival Analysis,
pubmed-meshheading:8420302-Treatment Outcome
|
|
pubmed:year |
1993
|
|
pubmed:articleTitle |
Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis.
|
|
pubmed:affiliation |
Department of Hematology, M.D. Anderson Cancer Center, Houston, Texas 77030.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
